About CHINARES PHARMA Company

China Resources Pharmaceutical Group Co., Ltd. (stock code: 3320) is a leading integrated pharmaceutical company in China. Its business scope covers the production, distribution and retail of pharmaceuticals and health products. The Group was founded in 2007 and has now developed into the top five pharmaceutical manufacturers in China and the top three distributors of pharmaceutical products in China (by revenue). The company successfully completed the global sale in Hong Kong in October 2016. Our manufacturing business covers R&D, production and sale of pharmaceutical products. We produce more than 782 types of pharmaceuticals. Our product portfolio includes chemicals, traditional Chinese medicine, biopharmaceuticals, and nutritional health products, covering a wide range of therapeutic fields, including cardiovascular, digestive and metabolic, high-volume intravenous injections, pediatrics, respiratory system, skin, etc. Furthermore, we own many well-known brands such as “999,” “Donga Ejiao,” “Shuanghe,” “Zizhu,” “Jiangzhong,” “Boya,” and “Kunyaku.” Our business covers categories such as colds, gastrointestinal, skin, pediatrics, orthopedics, blood products, etc. In the future, we will actively expand health management and chronic disease management products to meet the health needs of Chinese families throughout the week and at multiple levels. We regard R&D innovation as an important driving force for long-term development, and continue to increase R&D investment. We have 5 nationally certified engineering technology research centers, 3 state-certified enterprise technology centers, and nearly 70 provincial and municipal certified research centers, with over 2,400 R&D personnel. With our comprehensive product supply and extensive distribution network, we distribute products directly to hospitals and other medical institutions in China. We operate a nationwide distribution network composed of more than 200 logistics centers, strategically covering 28 provinces, municipalities and autonomous regions in China. The number of customers exceeds 140,000, including about 10,000 secondary and tertiary hospitals and 70,000 customers from primary medical institutions. Additionally, we operate 809 retail pharmacies under high-quality national or regional brands such as “Huaruntang” and “Dexin Bank”, including 253 pharmacies specializing in DTP (including 145 “dual channel” pharmacies).